B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

114.62 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 33,513
Open 114.62
Bid (Size) 113.00 (1,000)
Ask (Size) 113.80 (200)
Prev. Close 114.62
Today's Range 114.62 - 114.62
52wk Range 73.31 - 125.14
Shares Outstanding 2,531,374,696
Dividend Yield 2.97%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
From Merck & Co., Inc.
Via Business Wire
News headline image
Q4 Earnings Roundup: Merck (NYSE:MRK) And The Rest Of The Branded Pharmaceuticals Segment
Let’s dig into the relative performance of Merck (NYSE:MRK) and its peers as we unravel the now-completed Q4 branded pharmaceuticals earnings season. Looking... 
Via StockStory
Topics Artificial Intelligence Intellectual Property

Performance

YTD
+7.7%
+7.7%
1 Month
-1.5%
-1.5%
3 Month
+5.0%
+5.0%
6 Month
+31.5%
+31.5%
1 Year
+45.6%
+45.6%

More News

Read More
News headline image
Why Merck (MRK) Shares Are Trading Lower Today
Via StockStory
Topics Government Intellectual Property
Which S&P500 stocks are gapping on Tuesday? ↗
Via Chartmill
Merck & Co. Inc. (NYSE:MRK) Offers a Durable Dividend Backed by Strong Earnings ↗
Via Chartmill
News headline image
3 Reasons We Love Merck (MRK)
Via StockStory
Topics Stocks Supply Chain
News headline image
Better Pharma Dividend Stock: Novartis vs. Merck ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Tech Powerhouse: S&P 500 Eyes 12.6% Growth as AI Revolution Enters Second Gear
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
1 Profitable Stock for Long-Term Investors and 2 Facing Challenges
Via StockStory
News headline image
The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
From Daiichi Sankyo
Via Business Wire
News headline image
1 Momentum Stock on Our Buy List and 2 We Question
Via StockStory
News headline image
Which Dividend Pharma Stock Should a Value Investor Choose Today? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis
Via MarketMinute
Topics Bonds
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Terns Therapeutics, Inc. (Nasdaq – TERN), Whitestone REIT (NYSE – WSR), Rallybio Corporation (Nasdaq – RLYB), Day One Biopharmaceuticals, Inc. (Nasdaq - DAWN)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
ImmunityBio (IBRX): From R&D Speculation to Record Commercial Revenue
Via Finterra
Topics Economy World Trade
News headline image
Why Terns Pharmaceuticals Stock Rocked the Market in March ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
From Merck & Co., Inc.
Via Business Wire
News headline image
You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500. ↗
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer
Via MarketMinute
Topics Intellectual Property
News headline image
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
From Merck & Co., Inc.
Via Business Wire
News headline image
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
From Merck & Co., Inc.
Via Business Wire
News headline image
The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future
Via Finterra
Topics Artificial Intelligence Earnings Economy
News headline image
Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30
From Merck & Co., Inc.
Via Business Wire

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 114.62
When was Merck & Co last traded?
The last trade of Merck & Co was at 04/23/26 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 290.15B
How many shares of Merck & Co are outstanding?
Merck & Co has 290B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.